Preclinical Research in Down Syndrome: Insights for Pathophysiology and Treatments

Preclinical Research in Down Syndrome: From Bench to Bedside, Volume 251, the latest release in the Progress in Brain Research series, highlights new advances in the field. Chapters in this updated release include Exploring genetic and epigenetic mechanisms underlying cognitive deficits in Dow syndrome, The trisomy paradox: gene expression dysregulation domains, the Influence of allelic differences in mouse models of Down syndrome, Modelling Down syndrome in cells: From stem cells to organoids, Modelling Down syndrome in animals from the early stage to the new generation of models, Mapping behavioral landscapes in Down syndrome animal models, and more.
- Presents content by renowned authors who review the state-of-the-art in preclinical research and provide their views and perspectives for the future of the field- Provides extensively referenced chapters, thus giving readers a comprehensive list of resources on topics covered- Includes comprehensive and in-depth background information written in a clear form that is accessible to both specialists and non-specialists

1. Genetic and epigenetic pathways in Down syndrome: Insights to the brain and immune system from humans and mouse modelsY. Eugene Yu, Zhuo Xing, Catherine Do, Annie Pao, Eun Joon Lee, Sharon Krinsky-McHale, Wayne Silverman, Nicole Schupf and Benjamin Tycko2. Influence of allelic differences in Down syndromeRandall J. Roper, Laura Hawley and Charles R. Goodlett3. Modeling Down syndrome in cells: From stem cells to organoidsGillian Gough, Niamh L. O'Brien, Ivan Alic, Pollyanna A. Goh, Yeap Yee Jie, Jurgen Groet, Dean Nizetic and Aoife Murray4. Modeling Down syndrome in animals from the early stage to the 4.0 models and nextMaria del Mar Muñiz Moreno, Véronique Brault, Marie-Christine Birling, Guillaume Pavlovic and Yann Herault5. Mapping behavioral landscapes in Down syndrome animal models María Martínez de Lagrán6. Using mouse models to understand Alzheimer's disease mechanisms in the context of trisomy of chromosome 21Claudia Cannavo, Justin Tosh, Elizabeth M.C. Fisher and Frances K. Wiseman7. Focusing on cellular biomarkers: The endo-lysosomal pathway in Down syndromeAlexandra Botté and Marie-Claude Potier8. Translational validity and implications of pharmacotherapies in preclinical models of Down syndromeNoemí Rueda, Jesús Flórez, Mara Dierssen and Carmen Martínez-Cué9. Plasticity as a therapeutic target for improving cognition and behavior in Down syndromeCarmen Martínez-Cué and Mara Dierssen